All 50 states, Washington D.C., and four U.S. territories have reached a $7.4 billion settlement with Purdue Pharma, the company behind OxyContin, putting an end to the litigation against the Sacklers over the opioid crisis.

The settlement marks the largest of its kind and will bar the Sacklers from making, selling, or marketing opioids in the U.S. The agreement was led by California, Colorado, Connecticut, Delaware, Florida, Illinois, Massachusetts, Oregon, Pennsylvania, Tennessee, Texas, Vermont, Virginia, and West Virginia.

Purdue Pharma, under the Sackler families' leadership, invented, manufactured, and aggressively marketed opioid products for decades, leading to addiction and overdose deaths across the country. The settlement will allocate $7.4 billion to support opioid addiction treatment, prevention, and recovery programs over the next 15 years.

The Sacklers and Purdue increased their settlement contribution from $6 billion to $7.4 billion after a prior settlement was overturned by the U.S. Supreme Court. The funds will be distributed over the next 15 years, with a significant portion allocated in the first three years.

Connecticut Attorney General William Tong stated that while the settlement is significant, it is not enough to fully address the consequences of the Sackler family's actions. The future of Purdue will be determined by a board of trustees selected by participating states, and the company will be closely monitored to prevent lobbying or marketing of opioids.